Priavoid’s Phase 2 PRImus-AD trial of PRI-002, an oral peptide designed to break apart amyloid-beta oligomers, did not meet its primary efficacy endpoint:
change in Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 48.
The trial enrolled 304 people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, randomized to 300 mg or 600 mg of PRI-002 daily or placebo.
The company reported a favorable safety and tolerability profile, meeting the trial’s primary safety endpoint.
Some secondary and later exploratory analyses showed numerical differences favoring treatment, but most were not statistically significant. At Week 72, an exploratory ADAS-Cog13 analysis in the per-protocol group showed 35.9% less decline versus placebo (p=0.022); the company says the full dataset is expected in 2027.
The results are an early-stage signal, not evidence that PRI-002 meaningfully slows Alzheimer’s progression. The primary efficacy miss means any possible benefit needs confirmation in further studies.
Sources:
Category: Press Release - Priavoid
PRImus-AD: Recruitment for Phase II clinical trial ...
Priavoid Presents Initial Phase 2 Data Suggesting Favorable ...
Pharmaceuticals Press Release News | GlobeNewswire
Global Alzheimer's trial summit to unveil AriBio phase 3 pill ...
Priavoid to Present Initial Phase 2 Safety Data for Alzheimer's and ...
Four Alzheimer Drug Readouts to Watch at CTAD 2026
Initial Safety data | Priavoid GmbH - LinkedIn
CTAD 2026 Opens Monday: Alzheimer's Pill AR1001 Phase 3 Data Due Amid Antibody Benefit Doubts
Alzheimer's Disease: Mechanisms and Therapeutic Advances - PMC